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Prenatal Tobacco, Marijuana, Stimulant, and Opiate Exposure: Outcomes 
and Practice Implications
A
buse of drugs by pregnant women both in the United States and worldwide has raised many questions regarding the effects 
of prenatal drug exposure on the developing fetus and subsequent child outcomes. Studies using the neurobehavioral 
teratology model have been undertaken to determine specific prenatal drug effects on cognitive and behavioral development. 
Here we summarize the findings of studies that have investigated the developmental effects of prenatal exposure to tobacco, 
marijuana, stimulants, and opiates. These studies consider the timing and amount of prenatal exposure; other drug exposures; 
maternal characteristics; and other health, nutritional, and environmental factors. We review treatment options for pregnant, 
substance-dependent women and therapeutic interventions for exposed children.
S
everal well-designed and methodologically sound studies have described 
long-term effects of specific prenatal drug exposures on children’s health and 
development. Some longitudinal studies now extend into late adolescence 
and early adulthood and assess vulnerability to substance abuse and dependence.
The psychoactive substances widely used by women of childbearing age include 
alcohol, tobacco, marijuana, stimulants, and opioids. Here we summarize current 
knowledge of the effects of prenatal exposure to each of these drugs, except alcohol. 
The extensive research on prenatal alcohol exposure has been reviewed elsewhere 
(Manji et al., 2009; O’Connor and Paley, 2009; Paley and O’Connor, 2009). 
We also discuss promising findings from trials of interventions to help pregnant 
and postpartum substance-abusing women and prenatally drug-exposed children.
A MODEL FOR INVESTIGATION: NEUROBEHAVIORAL TERATOLOGY
The conceptual framework used to study prenatal drug exposure is neurobehavioral 
teratology, which addresses the impact of prenatal exposure to a foreign agent on 
a child’s central nervous system (CNS) and behavior. An important principle of 
teratology is that the harm caused by a toxic agent is a function of several factors, 
including the individual’s genetic makeup, the fetal and postnatal environment, the 
dose of the agent, and the developmental stage of the fetus at the time of exposure. 
Vorhees (1989) has added two specific neurobehavioral tenets:
•		Damage	to	the	CNS	during	the	prenatal	period	continues	to	have	effects	through	
fetal, neonatal, infant, and childhood development; and
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• CNS injury may result in behavioral impairments 
rather than physical birth defects. 
Mayes (2002) developed a model for neurobehav-
ioral teratology research that highlights the direct and 
indirect effects of prenatal drug exposure and the ongo-
ing reciprocal influences of CNS disruption, maternal 
characteristics, and environmental factors (Figure 1).
Women often abuse more than one drug, so a child’s 
problems frequently reflect the combined impact of 
multiple exposures. Substance-abusing women often 
also have other characteristics that can result in fetal 
harm, including high stress, lack of prenatal care, sexually 
transmitted infections, and high-risk behaviors such as 
drug-trade activities that expose them to violence. Once 
the child is born, influences that may come into play 
include low maternal IQ and verbal abilities, maternal 
psychopathology and chaotic lifestyle, exposure to lead or 
other toxins, and placement in institutional or foster care. 
The child’s CNS disruption can hinder his or her odds 
of reaching full developmental and academic potential 
directly and in combination with parental and environ-
mental factors. For example, a parent’s poor functioning 
in the caregiver role may compound the limiting impact 
that a child’s drug-related irritability and reduced self-
regulatory abilities have on opportunities for regular, 
language-rich dyadic exchange. A child’s drug-related 
cognitive and learning disabilities may derail social and 
vocational adjustment, and both may increase the odds 
of substance abuse, psychopathology, and involvement 
with the criminal justice system.
Because of this merging of effects, research to evaluate 
the specific effects of prenatal exposure to a particular 
drug must include assessment of key covariates known 
to affect the developmental and behavioral outcomes 
under study (Table 1). Studies must generally include 
an adequate number of subjects to achieve statistical 
power, and longitudinal studies must retain most sub-
jects over many years. A sufficiently large control group 
of similar sex, race, and socioeconomic status (SES) is 
essential. Recently, investigators have begun to apply new 
technologies to relate behavioral findings of prenatally 
drug-exposed children to brain structure and function 
and genetics. 
DRUG ACTION IN THE DEVELOPING FETUS
Although the placenta was once thought to protect 
the fetus against exposure to toxins, it is now known 
that metabolites of drugs, including cocaine, opiates, 
amphetamines, marijuana, and tobacco, enter the fetal 
bloodstream. Active metabolites can penetrate the fetal 
blood-brain barrier and interfere with early neuronal cell 
development or cause neuronal death (Lee et al., 2008). 
Researchers hypothesize that drug metabolites interact 
with an individual’s genetic makeup to influence cogni-
tive development and behavior. Thus, for example, some 
individuals may be genetically more susceptible than 
others to cocaine’s deleterious effects on development. 
Maternal drug abuse also affects the fetus indirectly. 
For example, crack cocaine, heroin, tobacco, and mari-
juana cause vasoconstriction that restricts the fetal oxygen 
supply. As well, substance abuse often conflicts with 
healthy maternal practices—such as eating a nutrient-rich 
diet and accessing prenatal care—that reduce pregnancy 
complications such as diabetes, preeclampsia, and pre-
term labor. Conditions that commonly co-occur with 
drug abuse, including sexually transmitted infections, 
depression, post-traumatic stress disorder, and exposure 
to chronic stress and violence, also may lead to fetal 
injury. Neonatal abstinence syndrome (NAS), which 
FIGURE 1. Model to Study Effects of Prenatal Drug Exposure on  
Developmental Outcomes
Adapted from Mayes, 2002.
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TABLE 1. Maternal and Caregiver Covariates to 
Be Considered in Prenatal Substance Exposure 
Research
Prenatal drug use
Socioeconomic status
Marital status
Parity 
Prenatal care
Psychological distress
Quality of home environment
Race
Cognitive ability
Years of education
weight suggests that the fetus has not obtained important 
nutrients and oxygen, which are important for optimal 
brain growth and neuronal development. Some evidence 
indicates that maternal tobacco use during pregnancy 
doubles the likelihood of sudden infant death syndrome 
(Salihu and Wilson, 2007; Table 2).
Neonates who were exposed to tobacco prenatally 
are more excitable, have greater muscle tension, require 
more handling to be calmed, and show more signs of 
CNS stress (e.g., abnormal sucking, excessive gas, gaze 
aversion) than unexposed infants (Law et al., 2003). 
Dose-response relationships have been established 
between maternal tobacco use, as measured by levels of 
salivary cotinine (the active metabolite of nicotine) or 
self-report, and signs of physiological stress.
Infant CNS functional abnormalities related to pre-
natal tobacco exposure include deficits in self-regulation 
(the infant’s ability to soothe or quiet itself) (Table 3). At 
2 to 4 weeks and at 7 months of age, prenatally tobacco-
exposed infants exhibited, compared with unexposed 
infants, more negative affect and manifestations of 
sadness, distress in response to limitations, decreased 
soothability, and fear during a test used to assess emo-
tional self-regulation (Schuetze and Eiden, 2007; Schue-
tze, Eiden, and Coles, 2007). Low birth weight and 
reduced head growth may underlie these disturbances.
Prenatal tobacco exposure has been consistently 
associated with lower IQ throughout childhood (Fried, 
2002; Herrmann, King, and Weitzman, 2008). In one 
study, children of women who smoked more than 16 
cigarettes a day while pregnant had a mean IQ in the 
average range, but 8 points lower than those of unexposed 
children (Fried, Watkinson, and Gray, 2003). Children 
prenatally exposed to tobacco are also at increased risk for 
attention problems during the early elementary school 
years (Cornelius et al., 2007; Langley et al., 2005; Lin-
net et al., 2003).
Conduct disorder can be an adverse outcome of 
prenatal tobacco exposure. In one study, adolescent 
children of mothers whose blood cotinine levels during 
pregnancy had been in the top 20 percent of those tested 
were twice as likely as the 20 percent of children with 
the least exposure to develop a conduct disorder (Braun 
et al., 2008). Postnatal exposure to secondhand smoke 
may also contribute substantially to diagnoses of conduct 
disorder in U.S. children (Braun et al., 2008). Recent 
data suggest that prenatal tobacco exposure may promote 
later conduct disorders by inhibiting the brain enzyme 
monoamine oxidase (MAO) during fetal development 
occurs after opiate use during pregnancy, puts the infant 
under physiological stress that increases the risk of health 
and possibly developmental problems.
Neuroimaging studies have revealed evidence of 
physiological brain changes in prenatally drug-exposed 
children, some of which correlated with the results of 
behavioral assessments. However, the studies need to 
be replicated, because they had small sample sizes and 
some lacked controls for possible confounding factors.
TOBACCO
Despite wide awareness that smoking is bad for both 
mother and developing fetus, in 2007, an estimated 
16.4 percent of pregnant American women were cur-
rent tobacco smokers (SAMHSA, 2008). Although 
pregnant women overall had lower smoking rates than 
nonpregnant women, pregnant 15- to 17-year-olds had 
higher smoking rates than their nonpregnant age mates.
Smoking increases a woman’s risk of ectopic preg-
nancy and placenta previa, both of which increase the 
odds of maternal mortality. Women who smoke dur-
ing pregnancy are somewhat less likely to develop pre-
eclampsia than those who do not smoke; however, among 
pregnant women who develop preeclampsia, smoking 
seems to increase mortality (Cnattingius, 2004). 
Tobacco use has also been linked to low birth weight 
and pregnancy complications, including prematurity, 
placental abruption, and intrauterine death. Low birth 
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(Baler et al., 2008). MAO participates in the regulation 
of the levels of monoaminergic neurotransmitters that 
are critical for fetal forebrain development.
Prenatal tobacco exposure has also been implicated 
in depression and anxiety in early childhood through 
late adolescence (Robinson et al., 2008). However, these 
internalizing symptoms have not received as much atten-
tion as conduct disorder, perhaps because they are less 
disruptive to families and classrooms. 
Prenatal tobacco exposure appears to increase the   
likelihood of tobacco use in childhood and early ado-
lescence. In one study, the risk differential of exposed 
and unexposed children at age 10 was more than five-
fold after controlling for environmental factors, other 
prenatal exposures, current maternal smoking, and child 
and maternal psychological covariates (Cornelius et al., 
2005). However, when the children in this study were 
14, prenatal tobacco exposure was no longer a significant 
predictor of their tobacco use when factors such as peer 
smoking were taken into account.
A magnetic resonance imaging (MRI) study of children 
aged 10 to 14 found reductions in cortical gray matter and 
parenchyma volumes, as well as head circumference, in 
those whose mothers had smoked while pregnant (Rivkin 
et al., 2008). Some researchers have suggested that prenatal 
tobacco exposure accelerates puberty among males (Fried, 
James, and Watkinson, 2001).
Treatment Recommendations 
Behavioral interventions are recommended as the first 
treatment options to help pregnant women stop smoking 
(Oncken and Kranzler, 2009; Slotkin, 1998). Several 
studies have demonstrated that contingency management 
(CM), a strategy that dispenses cash or other tangible 
prizes as incentives for achieving treatment goals, helps 
pregnant smokers maintain abstinence (Donatelle et al., 
2000; Heil, Scott, and Higgins, 2009; Higgins et al., 
2004). CM may be more effective with low-income preg-
nant smokers (Donatelle et al., 2004), whose quit rates 
with CM have ranged from 19 to 40 percent, compared 
with 6.6 to 20.5 percent with other behavioral interven-
tions. On its own, cognitive-behavioral therapy (CBT) 
yields only modest reductions in smoking-cessation 
rates among pregnant women. Combined treatment 
with CBT and nicotine replacement therapy (NRT) is 
more effective than CBT alone for pregnant moderate 
to heavy smokers (Osadchy, Kazmin, and Koren, 2009).
Although NRT is widely used and effective in the 
general population, there are concerns regarding its 
effectiveness for pregnant smokers and safety for the 
fetus. At issue is whether the risks for both mother and 
child outweigh the harmful effects of cigarette smoking 
on the fetus. Some researchers endorse the use of NRT 
under a physician’s close supervision in combination 
with behavioral interventions for moderate to heavy 
TABLE 2. Prenatal Drug Exposure: Potential Effects on Birth and Pregnancy Outcomes
TOBACCO MARIJUANA STIMULANTS HEROIN/OPIOIDS
Pregnancy complications No fetal growth effects Cocaine Stillbirth
Prematurity No physical abnormalities Prematurity Prematurity
Decreased birth weight Decreased birth weight Decreased birth weight
Decreased birth length Decreased birth length Decreased birth length
Decreased birth head  
circumference
Decreased birth head  
circumference
Decreased birth head  
circumference
Sudden infant death  
syndrome (SIDS)
Intraventricular hemorrhage Fetal and neonatal  
abstinence syndrome
Increased infant  
mortality rate
Methamphetamine Sudden infant death  
syndrome (SIDS)
Small for gestational age
Decreased birth weight
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smokers (Osadchy, Kazmin, and Koren, 2009). For heavy 
smokers, the benefits of NRT likely outweigh the risks 
of smoking during pregnancy because NRT (1) usually 
delivers a dose of nicotine less than or the same as what 
the person gets from smoking, (2) may eliminate fetal 
exposure to other toxins in cigarette smoke, and (3) 
may reduce the overall dose and duration of nicotine 
exposure (Oncken and Kranzler, 2003). When used, 
NRT therapy should begin as early in the pregnancy as 
possible, because a fetus may be especially sensitive to the 
adverse effects of nicotine exposure after the first trimester 
(Slotkin, 1998). The safety and efficacy of bupropion, 
another medication that is effective for smokers in the 
general population, has not been established for pregnant 
smokers (Oncken and Kranzler, 2003).
Abstinence from smoking during the first 2 weeks of 
a quit attempt is critical to long-term success (Higgins et 
al., 2006). It is therefore important to closely monitor 
early abstinence and adjust treatment as needed. Clini-
cians should continue to encourage women to quit even 
if they initially fail, because quitting at any time before 
childbirth reduces the risk of complications for both 
the mother and child.
MARIJUANA
The Ottawa Prenatal Prospective Study (OPPS), the 
Maternal Health Practices and Child Development 
(MHPCD) study, and other well-controlled studies 
have not implicated in utero marijuana exposure in any 
major fetal growth or physical abnormalities (Day et 
al., 1992; Fried and Smith, 2001; Table 2). The OPPS 
study did find a 1-week-shorter gestation period and 
two abnormalities associated with the visual system: true 
ocular hypertelorism (widely spaced eyes) and severe 
epicanthus (skin folds at the corners of the upper eyelids) 
among infants whose mothers smoked more than five 
joints per week while pregnant (Fried and Smith, 2001). 
However, the study authors concluded that the visual 
abnormalities were likely related to prenatal alcohol 
exposure rather than directly to marijuana exposure. 
Studies of neonatal neurobehavioral outcomes of pre-
natal marijuana exposure have observed mild withdrawal 
symptoms and poor autonomic control, particularly 
of state regulation (the ability to adjust one’s level of 
alertness as required for a task). Autonomic control was 
normal, however, when assessed at 6 months or 1 year 
of age (Fried, 1995; Table 3). 
The OPPS and MHPCD study examined the rela-
tionship between marijuana exposure and developmental 
problems throughout childhood. Children of women 
who smoked one or more marijuana joints a day during 
the first trimesters were more likely than controls to 
exhibit deficits in school achievement, particularly in 
reading and spelling (Goldschmidt et al., 2004). Pre-
natal marijuana exposure had persistent negative effects 
through age 16 on higher-order thinking, including 
problem solving, memory, planning, impulsivity, and 
attention (Fried, 2002; Fried, Watkinson, and Gray, 
2003; Goldschmidt et al., 2008; Richardson, Gold-
schmidt, and Larkby, 2007). Researchers did not find 
overall suppression of IQ.
Prenatal marijuana exposure may have long-term 
emotional and behavioral consequences. At age 10, chil-
dren who had been exposed to the drug during their first 
and third trimester of gestation reported more depressive 
symptoms than did unexposed controls (Gray, 2005). 
Among 16- to 21-year-olds, prenatal exposure to mar-
ijuana at least doubled the risk of both tobacco and 
marijuana use (Day, Goldschmidt, and Thomas, 2006; 
Porath and Fried, 2005). Adolescents with histories of 
daily prenatal marijuana exposure were 1.3 times as likely 
as those with less or no exposure to be high-frequency 
users of the drug, even after extensive control for other 
factors known to increase the risk of adolescent substance 
abuse (Day, Goldschmidt, and Thomas, 2006).
A recent functional MRI study of 18- to 22-year-olds 
linked prenatal marijuana exposure to altered neural 
functioning during a psychological test that involves 
remembering the placement of images that flash on a 
screen. Compared with a control group, the exposed 
group showed greater activation of neurons in the infe-
rior and middle frontal gyri and superior temporal gyri 
(Smith et al., 2006).
Treatment Recommendations 
Although they have not been studied specifically with 
pregnant users, CBT, motivational enhancement, and 
CM therapies have been demonstrated to be effective for 
reducing marijuana use (McRae, Budney, and Brady, 
2003). Controlled studies of pharmacotherapies for 
marijuana dependence are still needed, as is intervention 
research specifically targeting pregnant marijuana users.
COCAINE AND OTHER STIMULANTS 
Several recent prospective studies have examined the 
consequences of prenatal cocaine exposure. Relatively 
few, in contrast, have addressed prenatal exposure to 
methamphetamine, ecstasy, or methylphenidate (Ritalin 
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or Concerta) or other stimulant medications used to 
treat attention-deficit/hyperactivity disorder (ADHD).
Cocaine
At the height of the most recent crack-cocaine epidemic, 
in the late 1980s and the first half of the 1990s, an 
estimated 100,000 prenatally exposed children were 
born yearly in the United States. As many as 18 percent 
of live births were affected in some urban, primarily 
low-SES areas (Kandel, Warner, and Kessler, 1998; 
Ostrea et al., 1992; SAMHSA, 2000). Nearly 2 mil-
lion Americans  living today were prenatally exposed to 
cocaine, many of whom are now adolescents or young 
adults. Currently, an estimated 50,000 infants are 
born in the Nation each year having been prenatally 
exposed to cocaine.
Impact on neonatal and infant development
A majority of studies have reported that infants with his-
tories of prenatal cocaine exposure have reduced weight, 
head circumference, and/or length at birth (Bada et al., 
2005; Eyler et al., 1998; Singer et al., 2002b; Zucker-
man et al., 1989). A meta-analysis of 33 studies con-
ducted between 1989 and 1997 attempted to distinguish 
the direct effects of cocaine, as opposed to other risks 
commonly associated with cocaine abuse (e.g., abuse 
of other drugs, poor prenatal care) on these and other 
neonatal features and on pregnancy complications. The 
TABLE 3. Prenatal Drug Exposure: Potential Effects on Central Nervous System Development, Cognitive Function,  
and Behavior*
TOBACCO MARIJUANA STIMULANTS    OPIATES
Disturbed maternal-infant  
   interaction 
Excitability
Hypertonia
Stress abstinence signs
Conduct disorder
Reduced IQ
Aggression
Antisocial behavior
Impulsivity
ADHD
Tobacco use and dependence
Mild withdrawal symptoms 
Delayed state regulation
Reading, spelling difficulty
Executive function impairment
Early tobacco and  
marijuana use
Cocaine 
Neonatal/Infancy
Early neurobehavioral deficits:
Orientation, state regula-
tion, autonomic stability, 
attention,sensory and motor 
asymmetry, jitteriness
Poor clarity of infant cues  
  during feeding interaction
Delayed information  
  processing
General cognitive delay
Childhood
Lower nonverbal perceptual  
  reasoning
Lower weight for height 
Lower weight curve 
  trajectories
 Attention problems
Disruptive behaviors by  
  self-report and caregiver  
  report
Neonatal abstinence  
  syndrome
Less rhythmic swallowing
Strabismus
Possible delay in general  
  cognitive function
Anxiety
Aggression
Feelings of rejection
Disruptive/inattentive
  behavior
Methamphetamine
Poor movement quality  
   (3rd trimester exposure)
Lower arousal
Increased lethargy
Increased physiological stress
No mental or motor delay 
   (infant/toddler)
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results confirmed two problems as directly attributable 
to cocaine-related physiological stress in the prenatal 
environment: amniotic sac rupture more than 1 hour 
before labor begins and separation of the placenta from 
the uterus prior to delivery (Addis et al., 2001). 
Considerable evidence implicates prenatal cocaine 
exposure in subtle CNS abnormalities. When assessed 
with the Brazelton Neonatal Behavioral Assessment 
Scale, exposed infants showed deficits—albeit with much  
variability—in orientation, habituation, state regulation, 
autonomic stability, reflexes, tone, motor performance, 
irritability, alertness, and excitability (Singer et al., 2000). 
Compared with infants of mothers with similarly low 
SES who used other drugs during pregnancy, cocaine-
exposed infants showed higher rates of sensory and motor 
asymmetry, poor muscle tone, jitteriness (Singer et al., 
2000), and reduced novelty preference (Singer et al., 
1999). Both of these studies correlated greater prenatal 
cocaine exposure with poorer assessment scores in non-
verbal reasoning (Table 3).
Studies of the impact of prenatal cocaine exposure 
on development during the first 3 years of life have pro-
duced inconsistent results. For example, among low-SES 
children who may also have been prenatally exposed to 
alcohol, tobacco, and marijuana, Richardson and col-
leagues reported an association between cocaine expo-
sure during the second and third trimester of gestation 
and decrements in motor but not in mental abilities, as 
measured by the Bayley Scales of Infant Development 
(BSID) (Richardson, Goldschimdt, and Willford, 2008). 
In contrast, Frank and colleagues (2002) reported no 
correlation between cocaine exposure and either mental 
or motor scores on the same instrument. Singer and 
colleagues (2002a) used the BSID mental development 
index to compare prenatally cocaine-exposed and non-
cocaine-exposed 2-year-olds; the cocaine-exposed group 
scored 6 points lower and were twice as likely to have 
significant mental delay. Other research suggests that 
cocaine has an indirect effect on mental development 
through reduced head size (Behnke et al., 2006a).
Because cocaine targets the monoaminergic (dopa-
mine, norepinephrine, epinephrine, and serotonin) 
neurotransmitter systems, which are known to regulate 
attention, researchers have been interested in the drug’s 
impact on children’s capacity for attention. Studies 
indicate that prenatal cocaine exposure can impair visual 
attention, visual processing speed, and visual memory in 
infancy and throughout the first year of life (Jacobson 
et al., 1996; Singer et al., 1999; 2005).
How cocaine effects measured in infancy will play 
out in later childhood, adolescence, and adulthood is 
unclear. Early CNS abnormalities are considered poten-
tial early warning signs of underlying damage that may 
manifest later as self-regulatory problems. However, 
psychological assessments made before age 4 are gener-
ally weak predictors of how a child will perform later, 
although reduced novelty preference has been correlated 
with subsequent low IQ.
Impact on children 4 years and up
No childhood physical abnormalities have been defini-
tively attributed to prenatal cocaine exposure (Minnes et 
al., 2006). However, some evidence points to enduring 
growth consequences with lower weight-to-height ratios 
at 6 years of age (Minnes et al., 2006) and slower head 
circumference and weight trajectories from 1 to 10 years 
(Richardson, Goldschmidt, and Larkby, 2007).
As children grow older, psychological assessments 
become more stable. Subtle negative effects involving 
perceptual reasoning have been associated with prenatal 
cocaine exposure in children 4 to 9 years of age (Singer 
et al., 2004; 2008). Perceptual reasoning refers to one’s 
ability to envision solutions to nonverbal problems, such 
as recreating a spatial design with 3D colored blocks.
Problems of attention are particularly worrisome 
because they relate to poor school achievement and 
behavior problems. Prenatally cocaine-exposed 4- to 
7-year-olds performed below standard norms on tests 
that measure sustained attention (Bandstra et al., 2001) 
and selective attention (Noland et al., 2005). On the 
tests, which require subjects to watch a computer screen 
and respond appropriately each time a particular image 
or stimulus appears, they made more than the average 
number of incorrect responses, indicating impulsivity, 
and omitted more correct responses (Accornero et al., 
2007), indicating general inattention. 
Rule breaking, aggression, and other externalizing 
behaviors are associated with prenatal cocaine exposure 
and are attributed to a lack of self-regulation. Ratings com-
pleted by teachers, experimenters, and caregivers indicate 
that being prenatally cocaine-exposed, being male, and 
living in a high-risk environment are each independently 
predictive of aggressive behavior (Bendersky, Bennett, and 
Lewis, 2006). Linares and colleagues (2006) reported that 
among prenatally cocaine-exposed 6-year-olds: 
•  17 percent reported symptoms of oppositional defiant 
disorder, compared with 9 percent of unexposed age 
mates; and
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•	12 percent reported clinically elevated levels of ADHD 
symptoms, compared with 7 percent of unexposed peers.
At 10 years, boys with histories of prenatal cocaine 
exposure were more likely than unexposed boys to report 
high-risk traits, including aggression, substance use, 
and disregard for safety, on the Youth Risk Behavior 
Survey (Bennett, Bendersky, and Lewis, 2007). Teachers 
attribute high rates of behavioral problems, particu-
larly hyperactivity, to prenatally cocaine-exposed boys 
(Delaney-Black et al., 2004). One longitudinal study 
associated clinically elevated delinquent behavior with 
prenatal cocaine exposure in girls (Minnes et al., 2010). 
Some studies have found that recent caregiver drug use 
and psychological symptoms, but not prenatal cocaine 
exposure, predicted behavioral problems (Accornero 
et al., 2002; 2006; Sheinkopf et al., 2006; Warner et 
al., 2006b). Overall, however, the evidence suggests 
that children with prenatal cocaine exposure should be 
routinely screened for behavioral problems.
Imaging studies
Several researchers have deployed brain imaging to study 
the effects of prenatal cocaine exposure. These studies 
documented:
•	reduced	gray	matter	in	the	right	parietal	and	left	
occipital lobes and corpus callosum of 7- to 8-year-
olds (Dow-Edwards et al., 2006; Singer et al., 2006) 
and the caudate in a group averaging 14 years of age 
(Avants et al., 2007);
•	higher diffusion in white matter frontal projections 
at ages 10 to 11 (Warner et al., 2006a);
•		decreased	volume	of	the	right	anterior	cerebellum	at	
11 years of age (Dow-Edwards et al., 2006; Behnke 
et al., 2006b);
•	significantly smaller caudate in adolescents (Avants et 
al., 2007); and
•	also in adolescents, more functional connectivity in the 
default mode network (related to arousal regulation) 
and a greater signal increase when shown emotionally 
arousing stimuli (Li et al., 2011). 
Methamphetamine
In the only large-scale, well-controlled study of the effects 
of prenatal methamphetamine exposure—the Infant 
Development, Environment, and Lifestyle Study—
exposed infants were 3.5 times as likely as controls to 
be small for gestational age and had a lower average 
birth weight (Smith et al., 2006). By using the Neonatal 
Intensive Care Unit Network Neurobehavioral Scale, 
prenatal methamphetamine exposure has been associated 
with lower arousal from sleep, lack of energy, and physi-
ological symptoms indicating withdrawal. Preliminary 
findings indicate no impact on scores on the BSID at 
age 1, 2, or 3 (Lester and Lagasse, 2010). Additional 
followup of this cohort at later ages is needed to evaluate 
more subtle learning and behavioral problems.
Stimulant Medications for ADHD
There are growing concerns regarding the widespread 
use of stimulant medications for ADHD by women of 
childbearing age. To date, research has uncovered no 
clear pattern of negative effects on pregnancy or offspring 
when the medications are taken at therapeutic doses 
(Humphreys et al., 2007). However, no well-controlled 
prospective studies have been completed.
Treatment Recommendations 
All stimulant drugs, including prescribed medications, 
should be avoided during pregnancy. Women who wish 
to use prescribed stimulants during pregnancy should 
be assessed to determine whether the potential benefits 
to the mother outweigh any risk to the fetus (Goodman 
and Quinn, 2002). 
CM is a reliably effective treatment for cocaine depen-
dence in the general population, and the use of voucher-
based incentives has demonstrated promising results 
with pregnant women (Higgins, Alessi, and Dantona, 
2002). CM used in conjunction with behaviorally based 
substance abuse treatment can reinforce both cocaine 
abstinence and compliance with prenatal care in terms 
of weekly attendance at prenatal clinic visits (Elk et al., 
1995; 1998). In one study, CM did not greatly reduce 
dropout from residential treatment participation, but 
improved outpatient treatment retention during the 
transition from residential care (Svikis et al., 2007). 
Methamphetamine and cocaine abusers often 
respond similarly to treatment (Cretzmeyer et al., 2003). 
Although they have not been investigated with pregnant 
women, CBT, CM, and the Matrix Model may be the 
most effective treatment approaches for stimulant abuse 
and dependence (Winslow, Voorhees, and Pehl, 2007).
OPIATES
Rates of prenatal opiate exposure are difficult to obtain 
and vary widely from less than 1 percent to 21 percent, 
depending on the risk status of those screened and the 
time period (Ostrea, 1992; Yonkers et al., 2010). A U.S. 
multicenter study investigating the rates of prenatal 
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drug use by meconium analyses and maternal self-report 
indicated that 10.7 percent of 8,527 infants screened 
were exposed to cocaine or opiates (Lester et al., 2001). 
Although today more people abuse prescription pain 
relievers than illegal opiates, most research on opiates 
has involved subjects who are addicted to heroin or 
receiving opioid agonist therapy.
Fluctuations in an expectant mother’s daily heroin 
use due to voluntary abstinence or lack of access to the 
drug affect the fetus as well. If abrupt, these changes can 
precipitate fetal abstinence syndrome, which increases 
the risk of premature delivery, low birth weight, stillbirth, 
and sudden infant death syndrome (Joseph, Stancliff, and 
Langrod, 2000; Table 2). NAS occurs when birth abruptly 
deprives an infant of opiates it received via the placenta 
during gestation. NAS can manifest with serious but 
usually not persistent CNS symptoms, such as seizures, 
in 2 to 11 percent of neonates (Bandstra et al., 2010).
Heroin exposure decreases birth weight, birth length, 
and head circumference, but has not been associated 
with congenital malformations. Prenatal opiate expo-
sure has greater adverse impact than prenatal cocaine 
exposure on the infant CNS and autonomic nervous 
system (Das, Poole, and Bada, 2004), with effects that 
include abnormally high muscle tone, inconsolability, 
irritability, sneezing, stuffiness, excessive sucking, poor 
sucking ability, and high-pitched cry (Table 3). The 
high-pitched cry signifies a CNS abnormality that can 
result from increased cranial pressure or a congenital 
malformation. Infants who were exposed to both opiates 
and cocaine had louder and higher-pitched cries than 
infants exposed to either drug alone (Lester et al., 2002).
Followup studies of children prenatally exposed to 
opiates have had sample sizes too small to control for 
important covariates. Some have found evidence of 
delayed general cognitive function at 3 years (Wilson 
et al., 1979), lower verbal ability, and impaired reading 
and arithmetic skills (Ornoy et al., 2001); others found 
no cognitive delay at 6 to 13 years of age (deCubas and 
Field, 1993). Prenatal opiate exposure has frequently 
been associated with behavioral problems in childhood. 
One small study indicated that opiate-exposed children 
were more likely to have ADHD or other disruptive 
behavior diagnoses at 10 years of age (Hans, 1989). 
In summary, studies of prenatal opiate exposure 
and infants’ early cognitive development have yielded 
mixed results, but there seems to be a pattern linking the 
exposure to behavioral problems, including increases in 
ADHD and other disruptive behaviors.
Treatment Recommendations 
Since the late 1970s, it has been widely recognized that 
pregnant women addicted to heroin benefit from opioid 
agonist therapy with methadone. By stabilizing opiate 
withdrawal symptoms, such treatment reduces the use 
of illegal heroin and increases attendance in prenatal 
care, healthy diet, and other positive maternal health 
behaviors (SAMHSA, 2005; 2006). Methadone main-
tenance therapy stabilizes a mother’s opiate dose at a 
low level and reduces physiological withdrawal effects 
for the fetus. Heroin-addicted women who receive such 
therapy have infants with higher birth weights and lower 
rates of intrauterine growth retardation than those who 
are untreated. However, newborns whose mothers are 
maintained on methadone have a high incidence of 
NAS (SAMHSA, 2005; 2006). It is recommended that 
NAS be treated by giving a very low dose of opiate to 
the infant and then slowly tapering the dose (O’Grady, 
Hopewell, and White, 2009).
Studies that have evaluated whether treating expect-
ant mothers with methadone maintenance affects child 
development are difficult to compare because they have 
used different methodologies and measurements (Jones 
et al., 2008). A current NIDA-funded study called 
MOTHER is designed to address questions left open 
because of these methodological concerns. MOTHER 
will also seek to clarify whether methadone or buprenor-
phine is the superior pharmacotherapy for opioid-depen-
dent pregnant women and their children (Jones et al., 
2008). Buprenorphine, an alternative to methadone in 
opioid agonist therapy, is currently not FDA-approved  
for use during pregnancy because of a lack of adequate 
well-controlled studies with pregnant women.
Critical to the success of opioid agonist therapy is the 
use of supportive services, including behavioral therapy 
and assistance with domestic violence issues, employ-
ment, housing, food, and educational needs. Psychologi-
cal interventions are indicated to address disruptions 
in the mother-child relationship, guilt, depression, low 
self-esteem and victimization, and past trauma. 
INTERVENTIONS FOR DRUG-EXPOSED  
CHILDREN
Most research on intervention services for drug-exposed 
infants has evaluated intensive home-based services 
provided to substance-abusing mothers by community 
nurses. These services are designed to educate and 
support mothers to improve the home environment, 
parenting skills, and child development. Strengthen-
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ing maternal functioning has been the goal, because 
most studies of prenatal drug exposure have found that 
mothers’ level of psychological distress consistently 
predicts prenatally exposed children’s cognitive and 
behavioral outcomes (Minnes et al., 2010). Few stud-
ies have examined interventions that are drug-specific 
or directed to the infants themselves (Barnard and 
McKeganey, 2004).
Several studies demonstrate that early intervention 
services improve the home environment and mothers’ 
parenting behavior. In one, nurses visited substance-
abusing mothers and their infants every other week 
during the first 18 months of the child’s life (Black et 
al., 1994). The nurses guided the women through a 
curriculum about normal child development, child care, 
and safety; modeled parent-child activities that promote 
child development; addressed mothers’ concerns, such 
as relationship problems, affordable housing, and finan-
cial issues; and provided information about community 
resources and advocacy. The mothers who received 
the intervention were marginally more likely than a 
control group to be drug-free, keep primary health 
care appointments, be more emotionally responsive, 
provide a stimulating home environment, and score 
lower on a measure of child-abuse potential at the end 
of the 18-month study period.
As part of the Seattle Birth to 3 Program, parapro-
fessional advocates visited substance-abusing women 
and their children weekly for the first 6 weeks after 
birth, then at least biweekly, depending on need, for 
3 years. The advocates worked to establish trusting 
relationships with the mothers and motivate them to 
identify and work toward personal goals. They made 
and monitored followup on community referrals for 
drug treatment and other services for mother and child, 
and offered guidance and supervision to ensure that the 
child was in a safe environment and received appro-
priate care. At 36 months postpartum, 69 percent of 
the children receiving the intervention service were in 
what the research team considered to be an appropriate 
custody situation relative to their mother’s current use 
of alcohol/drugs (i.e., with mother in recovery for at 
least 6 months or not with mother unable to maintain 
abstinence), compared with 29 percent of children in 
a control group (Ernst et al., 1999). 
Butz and colleagues (2001) found that moth-
ers participating in another intensive home nurse 
intervention program reported a trend toward less 
parenting stress.
Child Development
Findings regarding the impact of intervention services 
on child development have been mixed, perhaps because 
the services usually consist of family case management 
rather than interventions directed specifically toward the 
children. Of note, even when children appeared to benefit 
from an intervention, exposed children in the comparison 
group who did not receive it usually performed within 
normal limits on developmental assessments.
Kilbride and colleagues (2000) followed a group of 
cocaine-exposed infants and their mothers for 3 years, 
providing intensive family case management, enriched 
nursery care, and regular evaluations, and found no dif-
ferences in mean cognitive, psychomotor, or language 
quotients compared with a group of exposed infants who 
received only routine followup and a group of unexposed 
infants. However, at 36 months, verbal scores of the 
cocaine-exposed infants who received case management 
were significantly higher than those of the routinely 
managed children, suggesting that “early intervention 
may have offset detrimental effects of the crack cocaine 
environment on verbal development.” 
In another study, infants who participated in an 
intensive home intervention program had significantly 
higher mental and psychomotor development scores 
compared with control infants (Schuler, Nair, and Ket-
tinger, 2003).
In contrast, Black and colleagues (1994) reported 
that children receiving home-based intervention services 
had somewhat higher cognitive scores relative to con-
trols at 6 months of age, but not at 12 and 18 months. 
Ernst and colleagues (1999) found that the cognitive 
development of children of substance-abusing mothers 
who received in-home advocacy services was equivalent 
at 36 months to that of children whose mothers did not 
receive the services.
Impact of Child Placement
Drug-exposed infants are often placed outside of the 
mother’s home in kinship, foster, or adoptive care to 
prevent child abuse or neglect. Researchers have inves-
tigated the possibility that such placement might avoid  
the ill effects of an unstable environment on children’s 
development, but studies show inconsistent results. 
For example:
•	Tyler and colleagues (1997) found that drug-exposed 
infants who remained with their biological moth-
ers demonstrated better cognitive development at 6 
months of age compared with infants placed in the 
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TABLE 4. Suggested Interventions Following Prenatal Drug  
Exposure
MATERNAL/CAREGIVER CHILD
Intensive home-based services 
• Mental health screening
• Parenting skills training
• Support for substance 
abstinence
Specific individual therapy 
• Speech and language 
• Occupational 
• Behavioral
Mental health treatment Early intervention/enrichment
Substance use treatment Ongoing cognitive and behavioral 
assessment
care of other relatives. In another study by Frank and 
colleagues (2002), infants in kinship care scored lower 
on mental development than infants in the care of 
their biological mothers or in foster care at 6 and 24 
months of age (Frank et al., 2002). In the latter study, 
children in foster care lagged behind children in their 
biological mothers’ care at 6 months, but surpassed 
them at 24 months.
•	Brown and colleagues (2004) observed more posi-
tive social-emotional development in 24-month-old 
cocaine-exposed children placed in nonparental care 
compared with those in parental care. Within the 
nonparental care group, those with nonkin caregivers 
scored higher in mental development, communicative 
gestures, and positive interactions during feeding than 
those in the care of relatives. 
•	Singer	and	colleagues	(2004;	2008)	consistently	found	
that over time, cocaine-exposed children fared better 
in cognitive and language development when placed 
in non-kin foster care or adoptive homes than when 
raised in a relative’s care or their birth mother’s custody. 
These children experienced better home environments 
and had more educated, less depressed caregivers than 
children who remained with their mothers or with 
relatives (Lewis et al., 2004; Singer et al., 2004; 2008).
• Bada and colleagues (2008) found that instability in 
living arrangements, such as multiple moves, changes 
in caregivers, and prolonged involvement with child 
protection services, predicted negative behavioral out-
comes during the first 3 years of life in a cohort of pre-
natally drug-exposed children. Total behavior problem 
scores on the Child Behavior Checklist increased 2.3 
and 1.3 points, respectively, with each move per year 
and each year of child protective services involvement. 
A Comprehensive Approach
Bandstra and colleagues (2010) have proposed a pre-
vention and intervention model for substance-abusing 
mothers and their infants that addresses the complex, 
multiple risk factors associated with maternal drug 
use. The model proposes the delivery of medical and 
behavioral health and parenting services to the mother, 
health and development services to the child, and care 
coordination and family support to reduce the barriers 
to accessing services.
Intervention services for this population need to 
extend beyond infancy and the toddler years, since prob-
lems in cognitive, language, and behavioral function-
ing may persist throughout childhood. Developmental 
assessment and intervention should continue during the 
preschool and school years, when children may benefit 
from enriched educational programs and screening for 
special education services. Problems can compound 
when cognitive demands increase during the early school 
years. Other critical transitional periods occur in the 
first, fourth, and sixth or seventh grades, when subtle 
learning or behavior problems may become more evident 
and lead to functional impairments (Weitzman et al., 
2002). Externalizing behavior problems and inattention 
in particular should not be ignored, as they are known to 
interfere with school achievement, school completion, 
and the development of healthy relationships.
Parents should be trained in the skills necessary to 
address behavior problems throughout childhood to 
prevent more serious disruptive and risky behaviors 
in adolescence and young adulthood. Moreover, birth 
mothers are likely to need ongoing intervention to main-
tain sobriety and to address mental health symptoms and 
parenting. As the effects of prenatal drug exposure and 
their relationships with environmental factors become 
more clearly understood, more specific early interven-
tion programs for drug-exposed children targeting areas 
of development that are known to be at risk should be 
developed and rigorously evaluated (Table 4).
CONCLUSION
Substance use during pregnancy can affect the developing 
fetus both directly, through passage of the drug through 
the placenta, and indirectly, through poor maternal 
health habits and environmental conditions. Numerous 
well-designed studies indicate that specific learning and 
behavior problems may result from prenatal exposure 
to tobacco and illicit drugs in combination with nega-
tive environmental conditions postpartum. Longitudi-
nal studies indicate that some of the negative effects of 
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cocaine, tobacco, and marijuana exposure persist into 
later childhood and adolescence. Although some early 
CNS symptoms remit over the first year of life, they may 
be precursors to later developmental outcomes.
Developmental outcomes of prenatally drug-exposed 
children are determined by factors including the specific 
drug or drugs, dosage, and timing of prenatal exposure 
as well as pre- and postnatal environmental conditions, 
including continued caregiver drug use, psychological 
symptoms, quality of the home environment, postnatal 
exposures to lead and other toxins, caregiver stability, and 
type of caregiver. The effects of negative environmental 
conditions associated with low SES may sometimes 
overshadow the effects of prenatal drug exposure.
Pregnancy is a unique time when a woman may seek 
treatment out of concern for the health and well-being 
of her child. To prevent postpartum substance abuse 
relapse, interventions should focus on cessation rather 
than temporary abstinence. The ongoing consequences 
of parental substance abuse on child growth and devel-
opment should be emphasized, and followup should 
continue into the postpartum period (Muhuri and Gfro-
erer, 2009). Interventions that reduce substance abuse 
in the general population are now being investigated in 
pregnant substance abusers with promising results. The 
use of CM appears to increase treatment retention and 
prolong abstinence in pregnant women with cocaine, 
opiate, and nicotine dependence. Some medications used 
to treat addiction, such as methadone, can be relatively 
safe for pregnant women and their babies. However, the 
safety and effectiveness of NRT for pregnant smokers 
requires further investigation. 
Additional research is needed on the development 
of specific interventions for drug-exposed infants and 
children. Each child must be individually assessed for his 
or her cumulative risk factors, domain of developmental 
difficulty, and the quality of the caregiving environ-
ment. Developmental outcomes may be optimized by 
interventions that occur early in life, are tailored for 
specific problem areas, and target caregivers’ level of 
stress, mental health functioning, continued substance 
abuse, and parenting interactions.
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